Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Pfizer
Eli Lilly and Company
Cancer Research UK
DL Analytics
Cancer Research UK
Corcept Therapeutics
Marengo Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.